Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with <i>MET</i> amplification (<i>MET</i>amp).

Le, Xiuning; Paz‐Ares, Luis; Meerbeeck, Jan Van; Viteri, Santiago; Galvez, Carlos Cabrera; Baz, David Vicente; Kim, Young‐Chul; Kang, Jin‐Hyoung; Schumacher, Karl-Maria; Karachaliou, Niki; Adrian, Svenja; Bruns, Rolf; Paik, Paul K.

doi:10.1200/jco.2021.39.15_suppl.9021

Cited by 37 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…70 New studies on the effect of Tepotinib in NSCLC with MET amplification have shown high and clinically meaningful activity, especially in patients who received Tepotinib in first line, where the ORR was 71%. 71 The most common side effect reported was peripheral edema (7%). 70…”

Section: Actionable Mutations In Lung Cancersmentioning

confidence: 99%

Emerging genetic biomarkers in lung adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

Comprehensive genomic profiling is a next-generation sequencing approach used to detect several known and emerging genomic alterations. Many genomic variants detected by comprehensive genomic profiling have become recognized as significant cancer biomarkers, leading to the development of major clinical trials. Lung adenocarcinoma has become one of the most targeted cancers for genomic profiling with a series of actionable mutations such as EGFR, KRAS, HER2, BRAF, FGFR, MET, ALK, and many others. The importance of these mutations lies in establishing targeted therapies that significantly change the outcome in lung adenocarcinoma besides the prognostic value of some mutations. This review sheds light on the development of the comprehensive genomic profiling field, mainly lung adenocarcinoma, and discusses the role of a group of mutations in this disease.

show abstract

Section: Actionable Mutations In Lung Cancersmentioning

confidence: 99%

Emerging genetic biomarkers in lung adenocarcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The cut-offs assessed in the GEOMETRY-mono 1 trial with capmatinib were GCNs of <4, 4 to 5, 6–9 and >10 [ 35 ]. Finally, the most recent analysis from the VISION trial with tepotinib, which utilized liquid biopsy, defined MET amplification positivity as MET GCN > 2.5 [ 86 ].…”

Section: Identifying Patients Most Likely To Benefit From Met -Targeted Therapiesmentioning

confidence: 99%

“…The first analysis presented at ASCO 2021 included 24 patients with MET amplification detected by Guardant360 liquid biopsy assay with MET GCN ≥ 2.5. Response rates in the seven patients that received tepotinib as first-line therapy was 42%, and 30% in the ten patients that were treated using it as second-line [ 86 ].…”

Section: What Are the Preferred First-line And Subsequent Therapies For Advanced Nsclc Patients With De Novo Met Amplimentioning

confidence: 99%

Canadian Consensus Recommendations on the Management of MET-Altered NSCLC

et al. 2021

View full text Add to dashboard Cite

In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence of several novel mesenchymal-epithelial transition (MET) factor-targeted therapies for the treatment of NSCLC, warrant the development of evidence-based consensus recommendations for the use of these agents. A Canadian expert panel was convened to define key clinical questions, review evidence, discuss practice recommendations and reach consensus on the treatment of advanced MET-altered NSCLC. Questions addressed by the panel include: 1. How should the patients most likely to benefit from MET-targeted therapies be identified? 2. What are the preferred first-line and subsequent therapies for patients with MET exon 14 skipping mutations? 3. What are the preferred first-line and subsequent therapies for advanced NSCLC patients with de novo MET amplification? 4. What is the preferred therapy for patients with advanced epidermal growth factor receptor (EGFR)-mutated NSCLC with acquired MET amplification progressing on EGFR inhibitors? 5. What are the potential strategies for overcoming resistance to MET inhibitors? Answers to these questions, along with the consensus recommendations herein, will help streamline the management of MET-altered NSCLC in routine practice, assist clinicians in therapeutic decision-making, and help ensure optimal outcomes for NSCLC patients with MET alterations.

show abstract

“…In the phase 2 VISION trial, once daily oral tepotinib 500 mg (450 mg active moiety) provided durable clinical responses in patients with advanced NSCLC harboring METex14 skipping alterations [9,10]. The study additionally showed antitumor activity of tepotinib in a separate cohort of patients with NSCLC with MET amplification as a primary driver [11]. Tepotinib is also active in combination with gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced NSCLC and MET-driven resistance to anti-EGFR therapy, as demonstrated in the phase 1b/2 INSIGHT trial [12].…”

Section: Introductionmentioning

confidence: 96%